Moderna enters gene editing from ground floor via Metagenomi deal

In its deal with Metagenomi, Moderna has decided to enter gene editing via access to next-generation nucleases to develop preclinical therapies for in vivo administration. The move sparked speculation in the markets about whether that decision boded ill for more advanced gene editing companies, which Moderna’s COVID-19 vaccine deals have given it firepower to acquire or partner with.

On Tuesday, Moderna Inc. (NASDAQ:MRNA) and Metagenomi Inc. announced a multi-year deal that combines Moderna’s mRNA and lipid nanoparticle (LNP) technologies with Metagenomi’s gene editing tools, which include next-generation CRISPR-based nucleases. Metagenomi will receive an undisclosed upfront payment, equity investment and research funding, and is eligible for undisclosed milestones, plus royalties. ...